475 related articles for article (PubMed ID: 29720517)
1. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
2. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
4. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
5. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
[TBL] [Abstract][Full Text] [Related]
6. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
8. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
[TBL] [Abstract][Full Text] [Related]
9. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
[TBL] [Abstract][Full Text] [Related]
10. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G
Front Immunol; 2020; 11():713. PubMed ID: 32373131
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.
Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W
Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310
[TBL] [Abstract][Full Text] [Related]
12. Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
Pendzialek J; Roose K; Smet A; Schepens B; Kufer P; Raum T; Baeuerle PA; Muenz M; Saelens X; Fiers W
Antiviral Res; 2017 May; 141():155-164. PubMed ID: 28257797
[TBL] [Abstract][Full Text] [Related]
13. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
14. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
[TBL] [Abstract][Full Text] [Related]
16. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
17. Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART
Tuyishime M; Dashti A; Faircloth K; Jha S; Nordstrom JL; Haynes BF; Silvestri G; Chahroudi A; Margolis DM; Ferrari G
Front Immunol; 2021; 12():710273. PubMed ID: 34484212
[TBL] [Abstract][Full Text] [Related]
18. Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization.
McInerney TL; Dimmock NJ
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1645-54. PubMed ID: 11779352
[TBL] [Abstract][Full Text] [Related]
19. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection.
Briant L; Coudronnière N; Robert-Hebmann V; Benkirane M; Devaux C
J Immunol; 1996 May; 156(10):3994-4004. PubMed ID: 8621941
[TBL] [Abstract][Full Text] [Related]
20. A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells.
Brey CU; Proff J; Teufert N; Salzer B; Brozy J; Münz M; Pendzialek J; Ensser A; Holter W; Lehner M
Sci Rep; 2018 Nov; 8(1):17453. PubMed ID: 30487534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]